You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
諾唯贊(688105.SH):與我國境內一家生物醫藥企業就呼吸道感染性疾病的單克隆抗體的研究開發與商業化項目達成合作
格隆匯 03-12 17:43

格隆匯3月12日丨諾唯贊(688105.SH)公佈,公司(“乙方”)於近日與我國境內一家生物醫藥企業(“協議對方”或“甲方”)就一項關於呼吸道感染性疾病的單克隆抗體(“目標單克隆抗體”或“目標抗體”)的研究開發與商業化項目達成合作,簽訂了《合作框架協議》。上述協議將作為後續合作的指導性文件,公司與協議對方將根據項目進展簽署進一步合作協議,具體實施內容和項目進度存在一定不確定性。

專利轉讓費用包括500萬元首付款及里程碑款4000萬元,具體里程碑事件包括專利完成轉讓變更登記、臨牀階段里程碑以及獲得上市批准,預計公司將收到專利轉讓費用合計不超過4500萬元。

如項目進入正式合作階段,待目標產品在合作區域內獲批上市後,公司將根據協議約定的銷售分成年限(最長不超過獲得銷售收益後的連續10年或轉讓抗體專利有效期),在不同時間段內獲得目標產品在合作區域淨銷售額的4%或2%作為銷售分成。

公司預計收到的專利里程碑款及最終銷售分成金額存在一定不確定性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account